Who takes quetiapine — and why it matters
Quetiapine (Seroquel) is a second-generation antipsychotic with a primary licence for schizophrenia and bipolar disorder. However, it is also widely prescribed at lower doses — typically 25mg to 100mg — as an off-label treatment for insomnia, anxiety and agitation, including in people with no primary psychotic diagnosis.
This distinction matters because the approach to deprescribing is significantly different depending on the indication. People with schizophrenia or acute bipolar disorder require a very different clinical conversation about reduction than people who were prescribed quetiapine for sleep or anxiety and no longer wish to take it.
Our deprescribing service is appropriate for people in the latter group — those on quetiapine for sleep, anxiety or mood stabilisation without an active primary psychotic diagnosis, who are currently stable and wish to reduce with proper support.
Quetiapine withdrawal symptoms
Quetiapine affects multiple receptor systems — including histamine (which explains its sedating effect), serotonin, dopamine and adrenergic receptors. When it is reduced or stopped, several of these systems can rebound, producing a range of withdrawal symptoms:
- Severe insomnia — often the most distressing symptom, particularly for those who were prescribed it for sleep
- Nausea and vomiting — particularly in the days immediately following a reduction
- Anxiety and agitation — sometimes intense, reflecting histamine and adrenergic rebound
- Dizziness and headaches
- Irritability and mood instability
- Sweating and flu-like sensations
- Vivid dreams and nightmares once sleep begins to return
The sleep disruption in particular can feel extreme in the first weeks of reduction — especially for someone who has come to rely entirely on quetiapine for sleep. This does not mean sleep will not return. It means the nervous system needs time to re-establish its own sleep architecture, and that this process needs to be supported with appropriate pacing and, where needed, behavioural sleep strategies.
How quetiapine reduction is approached
As with all long-term psychiatric medications, the key principle is gradual, proportional reduction guided by response rather than a fixed timeline. Specific considerations for quetiapine include:
- Quetiapine is available in immediate-release (IR) and extended-release (XR) formulations — IR is generally used during tapering as it allows more flexible dose management
- The smallest available tablet is 25mg, which is adequate for most tapering steps until the very lowest doses
- Liquid preparations or compounded lower-dose formulations may be needed for the final stages
- Sleep support strategies — sleep hygiene, stimulus control, relaxation techniques — are valuable alongside the taper to help re-establish natural sleep patterns
- Reductions are typically made every two to four weeks, with the pace adjusted based on how sleep and mood are responding
Key points about stopping quetiapine
- Sleep disruption is the most common and most distressing withdrawal symptom — it usually improves over weeks to months with the right support
- Never stop quetiapine abruptly after prolonged use, particularly at higher doses
- Reductions at lower doses (below 50mg) often need to be made more slowly than earlier steps
- Behavioural sleep support alongside the taper significantly improves outcomes
- Nausea in the first few days after a reduction is normal and usually settles within a week
- People on quetiapine for a primary psychotic illness should not reduce without specialist psychiatric review
Important — diagnosis matters
This page is intended for people taking quetiapine off-label for sleep, anxiety or mood support without a primary diagnosis of schizophrenia, schizoaffective disorder or acute bipolar disorder. If you have a primary psychotic illness and are considering reducing quetiapine, please discuss this with your treating psychiatrist before making any changes. We can support this conversation as part of our second opinion service.
For GPs considering referral
We accept referrals for patients on quetiapine who wish to reduce — particularly those prescribed it off-label for sleep or anxiety who are currently stable and motivated to stop. Our assessment will confirm the clinical appropriateness of reduction, develop a bespoke taper plan, and provide ongoing monitoring. We can advise on formulation management and issue private prescriptions as needed. We do not accept patients with active psychotic illness or recent hospitalisation without a fuller clinical discussion first.
Our approach
How we support quetiapine reduction
We begin with a thorough assessment to confirm that reduction is clinically appropriate in your case, understand your reasons for wanting to stop, and establish your current baseline of stability. We then build a taper plan that accounts for quetiapine's specific pharmacology — including the particular challenge of sleep disruption — and provides a clear, manageable pathway.
- Full psychiatric assessment to confirm appropriateness of reduction
- Bespoke taper plan with sleep management support built in
- Advice on formulation throughout the taper
- Private prescriptions where needed
- Written communication to your GP at each key stage
Related reading
Quetiapine can be reduced safely — even when you have come to depend on it for sleep.
The nervous system has a remarkable capacity to recover. It simply needs more time, and more support, than it is usually given.